SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark gets first-to-file status for 3 drugs in US

03 Jul 2009 Evaluate

Glenmark Pharmaceuticals has received first-to-file status for three of its abbreviated new drug applications (ANDA) that have combined revenues of over $2 billion (about Rs 9,600 crore at current exchange rates) in the US. The company has received first-to-file status for Zetia (generic name Ezetimibe), Tarka (Trandolapril + Verapamil) and Cutivate (Fluticasone lotion).

First-to-file status typically recognises a generic company as being the first to file a para IV application challenging a particular patent and seeking to manufacture generic versions of a drug which, at present, does not have generic competition.

With the first-to-file status comes a 180-day marketing exclusivity (from the date of approval of the ANDA), during which the Food and Drug Adminstration may not approve another ANDA for such generic product. During this period, the first-to-file generic company can reap huge benefits on the sale of the generic drug, which is typically sold at a price ranging from 70-80% of the brand product price. This would be before other generic equivalents enter the market following the expiration of the 180-day exclusivity period.

The latest first-to-file status was granted for Ezetimibe in April this year. Litigation for all three filings is in various stages, but if Glenmark wins, it will get a 180-day exclusive marketing period. Six month marketing exclusivity periods are much sought after, as it gives a company an edge over the competition in gaining market share before the space becomes highly competitive.

crackcrack

Glenmark Pharma Share Price

2229.65 -18.25 (-0.81%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×